Cancer Biology Research Laboratory (CBRL) was established by Dr. Mona Mostafa Mohamed on 2007 when she got fund from Cairo University and Avon Foundation (USA). Avon foundation fund was directed to Cairo University on Dr. Mona Mostafa Mohamed’s behalf to continue breast cancer research in Egypt in collaboration with Dr. Bonnie Sloane, Wayne State University, Detroit, Michigan, USA.
Our research focused on:
a) Studying cell-cell communication between breast carcinoma cells and immune cells (EL-Shinawi et al., 2010) to understand the role of immune cells such as tumor associated macrophages in development of the disease and metastasis (Mohamed et al., 2008; Mohamed et al., 2010; Mohamed, et al. 2014).
b) Determining expression profiles of tumor associated monocytes/macrophage in regard to cytokines, chemokines; growth factors and signaling molecules that stimulate metastasis and testing effects of their inhibition (Mohamed 2012; Mohamed et al., 2014).
c) Characterizing molecular alterations of intracellular signaling pathways within Studying how virus-infected carcinoma cells may contribute to breast cancer disease etiology (El-Shinawi et al., 2013).
d) Investigating epigenetic mechanisms associated with inflammatory breast cancer progression (Mohamed et al., 2014).
e) Studying the role of candidate cytokines found to be associated in breast carcinogenesis of Egyptian patients in the transactivation of epidermal growth factors receptors signaling pathways and identifying therapeutically target molecules.
f) In addition we are interested in analyzing the molecular role of proteoglycans and glycosaminoglycans in the pathogenesis of malignant and inflammatory diseases. We aim to find novel molecular mechanisms through which the heparin sulfate proteoglycan Syndecan-1 modulates stem–like cells and their environments that in turn pave the way for innovations in experimental treatment of cancers and will likely continue to offer vast avenues for understanding IBC and to improve patient outcome. On one side of our research, we are deciphering the role of Syndecan-1, a modulator of inflammation and malignant cell behavior in breast cancer, with a focus on its role in cancer stem cell biology, including regulatory aspects involving microRNA. Furthermore, we are examining the functional interplay between immunomodulatory cells within the tumor microenvironment and stem-like cells of IBC, focusing on the key role of Syndecan-1 in fine-tuning such reciprocal interaction. On the other side, we are characterizing expression profiles of dysregulated microRNAs and their downstream targets to identify potential new biomarkers for IBC and non-IBC patients (Ibrahim et al., 2012)